Allergy to component of vaccine
Conditions
Interventions
Quavalent influenza vaccination 2 doses then 1 dose next 2 week
Collection of hemaglutination titer for influenza 4 strains before first vaccination and next 2,
4 week,Quavalent influenza vaccination 1 dose
Collection of hemaglutination titer for influenza 4 strains before first vaccination and next 2,
4 week
Experimental Drug,Active Comparator Drug
Double dose influenza vaccine with a booster,Standard dose influenza vaccine
Sponsors
Goverment
Goverment
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients undergoing hemodialysis OPD at BAH Age ≥ 18 years Sp Kt/V ≥ 1.2 Hb ≥ 9 g/dL Serum albumin ≥ 3 g/dL Serum ferritin < 1,000 ng/mL
Exclusion criteria
Exclusion criteria: Immunocompromised host e.g. HIV Taking any immunosuppressive agent for 3 months subsequent months before enrollment Having been hospitalized for 3 months subsequent months before enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with seroprotection of influenza infection Before vaccination, 2 weeks and 4 weeks after vaccination Hemoagglutination inhibitor titer for influenza 4 strains | — |
Secondary
| Measure | Time frame |
|---|---|
| Seroprotection and seroconversion 4 weeks after first vaccination Hemoagglutination inhibitor titer for influenza 4 strains | — |
Countries
Thailand
Contacts
Public ContactEkapol Ritveeradej
Bhumibol Adulyadej hospital
Outcome results
None listed